Ceapro Inc. (CZO.V)
| Previous Close | 0.5500 |
| Open | 0.5600 |
| Bid | 0.5200 x 0 |
| Ask | 0.5600 x 0 |
| Day's Range | 0.5200 - 0.5600 |
| 52 Week Range | 0.5000 - 0.9200 |
| Volume | |
| Avg. Volume | 30,527 |
| Market Cap | 40.397M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | 26.00 |
| EPS (TTM) | 0.0200 |
| Earnings Date | Nov. 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.
- Simply Wall St.
Ceapro's (CVE:CZO) Returns On Capital Not Reflecting Well On The Business
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
- GlobeNewswire
Ceapro Inc. Announces R&D Funding to Support PGX Technology Project
– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are receiving advisory services and up to
